1. Home
  2. AAT vs ANAB Comparison

AAT vs ANAB Comparison

Compare AAT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Assets Trust Inc.

AAT

American Assets Trust Inc.

HOLD

Current Price

$19.48

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$54.21

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AAT
ANAB
Founded
1967
2005
Country
United States
United States
Employees
208
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
AAT
ANAB
Price
$19.48
$54.21
Analyst Decision
Hold
Strong Buy
Analyst Count
2
10
Target Price
$20.00
$62.20
AVG Volume (30 Days)
491.6K
409.7K
Earning Date
05-05-2026
04-05-2026
Dividend Yield
7.21%
N/A
EPS Growth
N/A
15.79
EPS
0.92
N/A
Revenue
$436,204,000.00
$91,280,000.00
Revenue This Year
$6.32
$135.51
Revenue Next Year
N/A
N/A
P/E Ratio
$20.50
N/A
Revenue Growth
N/A
432.03
52 Week Low
$16.69
$14.01
52 Week High
$22.79
$57.65

Technical Indicators

Market Signals
Indicator
AAT
ANAB
Relative Strength Index (RSI) 59.25 61.02
Support Level $17.80 $53.00
Resistance Level $19.32 $56.28
Average True Range (ATR) 0.45 3.49
MACD 0.08 0.37
Stochastic Oscillator 85.50 70.80

Price Performance

Historical Comparison
AAT
ANAB

About AAT American Assets Trust Inc.

American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: